This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moving Average Crossover Alert: Coherus BioSciences
by Zacks Equity Research
Coherus BioSciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
5 Biotech Stocks Defying the Medicare-for-All Scare
by Swarup Gupta
Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.
Coherus (CHRS) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Coherus BioSciences (CHRS): Moving Average Crossover Alert
by Zacks Equity Research
Coherus BioSciences, Inc. (CHRS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal third-quarter results next week. Investors focus is expected to be on the commercialization plan for Epidiolex.
Implied Volatility Surging for Coherus BioSciences (CHRS) Stock Options
by Zacks Equity Research
Investors in Coherus BioSciences (CHRS) need to pay close attention to the stock based on moves in the options market lately.
Amgen (AMGN) Gets CHMP Nod to Expand EU Label of Neulasta
by Zacks Equity Research
Amgen (AMGN) gains positive opinion from the CHMP to update the label of Neulasta to include Neulasta Onpro Kit, an innovative delivery system.
AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.
Coherus Stock Plummets as FDA Rejects Neulasta Biosimilar
by Zacks Equity Research
Coherus Biosciences, Inc. (CHRS) shares declined nearly 24% in yesterday's trading as it announced that it has received a complete response letter (CRL) from the FDA for its biosimilar version of Amgen Inc's (AMGN) blockbuster drug, Neulasta.
Implied Volatility Surging for Coherus Biosciences (CHRS) Stock Options
by Zacks Equity Research
Investors in Coherus Biosciences, Inc. (CHRS) need to pay close attention to the stock based on moves in the options market lately.
AbbVie Down on Humira Patent Loss: Is More Damage in Store?
by Zacks Equity Research
AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),
Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock?
by Zacks Equity Research
Investors in COHERUS BIOSCIENCES, INC. (CHRS) need to pay close attention to the stock based on moves in the options market lately.
Coherus Offers Positive Phase III Data on Humira Biosimilar
by Zacks Equity Research
Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.
Bear of the Day: AbbVie (ABBV)
by Kevin Cook
Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus